NCT06208592

Comparative Study of Anaconda System Use Versus Conventional Sedation in COVID-19 Patients.

Comparative Study of Sedative Requirement Using Sevoflurane With Anaconda Device Versus Conventional Sedation in Patients With COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 43 (actual)
• Sponsor: Hospital Español de Mexico · Academic / Other
• Sex: All
• Age: 27 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.

Detailed description

Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.

Conditions

• COVID-19
• Respiratory Failure

Interventions

Type	Name	Description
DEVICE	Sevoflurane with AnaConDa	Sevoflurane administered with AnaConDa device

Timeline

• Start date: 2020-05-30
• Primary completion: 2020-09-18
• Completion: 2020-11-06
• First posted: 2024-01-17
• Last updated: 2024-01-26

Locations

1 site across 1 country: Mexico